Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Monoamine Oxidase Inhibitors: From Classic to New Clinical Approaches
Pablo Duarte, Antonio Cuadrado, Rafael León
Handbook of experimental pharmacology (2020), pp. 229-259
Closed Access | Times Cited: 32

Showing 1-25 of 32 citing articles:

Emerging evidence for astrocyte dysfunction in schizophrenia
Eva Cristina de Oliveira Figueiredo, Corrado Calì, Francesco Petrelli, et al.
Glia (2022) Vol. 70, Iss. 9, pp. 1585-1604
Open Access | Times Cited: 52
Therapeutic Role of Heterocyclic Compounds in Neurodegenerative Diseases: Insights from Alzheimer’s and Parkinson’s Diseases
Nidhi Puranik, Minseok Song
Neurology International (2025) Vol. 17, Iss. 2, pp. 26-26
Open Access | Times Cited: 1
Monoamine oxidase B inhibitors based on natural privileged scaffolds: A review of systematically structural modification
Yangjing Lv, Zhiyuan Zheng, Renzheng Liu, et al.
International Journal of Biological Macromolecules (2023) Vol. 251, pp. 126158-126158
Closed Access | Times Cited: 13
Microbiota-Induced Epigenetic Alterations in Depressive Disorders Are Targets for Nutritional and Probiotic Therapies
Shabnam Nohesara, Hamid M. Abdolmaleky, Jin‐Rong Zhou, et al.
Genes (2023) Vol. 14, Iss. 12, pp. 2217-2217
Open Access | Times Cited: 13
An updated patent review on monoamine oxidase (MAO) inhibitors
Paolo Guglielmi, Simone Carradori, Ilaria D’Agostino, et al.
Expert Opinion on Therapeutic Patents (2022) Vol. 32, Iss. 8, pp. 849-883
Closed Access | Times Cited: 22
A review of monoamine oxidase (MAO) inhibitors in tobacco or tobacco smoke
Sa Weon Hong, Paul Teesdale‐Spittle, Rachel Page, et al.
NeuroToxicology (2022) Vol. 93, pp. 163-172
Closed Access | Times Cited: 19
Network-Based Drug Optimization toward the Treatment of Parkinson’s Disease: NRF2, MAO-B, Oxidative Stress, and Chronic Neuroinflammation
Pablo Duarte, Francisco J. Sanchez-Porro, Enrique Crisman, et al.
Journal of Medicinal Chemistry (2025) Vol. 68, Iss. 3, pp. 3495-3517
Closed Access
Resveratrol Analogues as Dual Inhibitors of Monoamine Oxidase B and Carbonic Anhydrase VII: A New Multi-Target Combination for Neurodegenerative Diseases?
Simone Carradori, Marialuigia Fantacuzzi, Alessandra Ammazzalorso, et al.
Molecules (2022) Vol. 27, Iss. 22, pp. 7816-7816
Open Access | Times Cited: 17
The Associations between COMT and MAO-B Genetic Variants with Negative Symptoms in Patients with Schizophrenia
Zoran Madžarac, Lucija Tudor, Marina Šagud, et al.
Current Issues in Molecular Biology (2021) Vol. 43, Iss. 2, pp. 618-636
Open Access | Times Cited: 22
Reactive Oxygen Species
Harald Schmidt, Pietro Ghezzi, Antonio Cuadrado
Handbook of experimental pharmacology (2021)
Closed Access | Times Cited: 21
A Multitarget Approach against Neuroinflammation: Alkyl Substituted Coumarins as Inhibitors of Enzymes Involved in Neurodegeneration
Emanuela Berrino, Simone Carradori, Fabrizio Carta, et al.
Antioxidants (2023) Vol. 12, Iss. 12, pp. 2044-2044
Open Access | Times Cited: 8
Ischemia–Reperfusion Injury: Molecular Mechanisms of Pathogenesis and Methods of Their Correction
R. G. Goncharov, М. Г. Шарапов
Molecular Biology (2023) Vol. 57, Iss. 6, pp. 1143-1164
Closed Access | Times Cited: 8
Novel Series of Dual NRF2 Inducers and Selective MAO-B Inhibitors for the Treatment of Parkinson’s Disease
Pablo Duarte, Patrycja Michalska, Enrique Crisman, et al.
Antioxidants (2022) Vol. 11, Iss. 2, pp. 247-247
Open Access | Times Cited: 11
Importance of Indazole against Neurological Disorders
Dilipkumar Pal, Pooja Sahu
Current Topics in Medicinal Chemistry (2022) Vol. 22, Iss. 14, pp. 1136-1151
Closed Access | Times Cited: 11
Non-cytochrome P450 enzymes involved in the oxidative metabolism of xenobiotics: Focus on the regulation of gene expression and enzyme activity
Xiaoyan Pang, Chongzhuang Tang, Runcong Guo, et al.
Pharmacology & Therapeutics (2021) Vol. 233, pp. 108020-108020
Closed Access | Times Cited: 13
The Effects of Safinamide Adjunct Therapy on Depression and Apathy in Patients With Parkinson's Disease: Post-hoc Analysis of a Japanese Phase 2/3 Study
Nobutaka Hattori, Yuki Kogo, Michinori Koebis, et al.
Frontiers in Neurology (2022) Vol. 12
Open Access | Times Cited: 9
Beyond cardiovascular risk: Implications of Familial hypercholesterolemia on cognition and brain function
Jade de Oliveira, Eduardo Luiz Gasnhar Moreira, Andreza Fabro de
Ageing Research Reviews (2023) Vol. 93, pp. 102149-102149
Closed Access | Times Cited: 5
Recent advances in potential enzymes and their therapeutic inhibitors for the treatment of Alzheimer's disease
Zahra Farajzadeh Vahid, Morteza Eskandani, Hamed Dadashi, et al.
Heliyon (2024) Vol. 10, Iss. 23, pp. e40756-e40756
Open Access | Times Cited: 1
6-Benzyloxyphthalides as selective and reversible monoamine oxidase B inhibitors with antioxidant and anti-neuroinflammatory activities for Parkinson’s disease treatment
Qing Song, Guangjun Yu, Wei Li, et al.
Bioorganic Chemistry (2022) Vol. 120, pp. 105623-105623
Closed Access | Times Cited: 7
Antidepressant-like Effects of Polygonum minus Aqueous Extract in Chronic Ultra-Mild Stress-Induced Depressive Mice Model
Muhammad Irfan Bashir, Nur Hidayah Kaz Abdul Aziz, Dzul Azri Mohamed Noor
Behavioral Sciences (2022) Vol. 12, Iss. 6, pp. 196-196
Open Access | Times Cited: 7
Biologically Active 2-Oxazolidinone Derivatives Beyond Antibacterial Activities
Leer Yuan, Rong Sheng, Mengying Guan, et al.
Current Medicinal Chemistry (2022) Vol. 30, Iss. 23, pp. 2672-2689
Closed Access | Times Cited: 6
Synthesis, in vitro, and in silico studies of new derivatives of diphenylpiperazine scaffold: A key substructure for MAO inhibition
Lamiaa O. El-Halaby, Walaa M. El-Husseiny, Shahenda M. El‐Messery, et al.
Bioorganic Chemistry (2023) Vol. 143, pp. 107011-107011
Closed Access | Times Cited: 3
Ischemia-Reperfusion Injury: Molecular Mechanisms of Pathogenesis and Methods of Their Correction
R. G. Goncharov, М. Г. Шарапов
Молекулярная биология (2023) Vol. 57, Iss. 6, pp. 1150-1174
Closed Access | Times Cited: 3
How to address the complexity of multi-targeted drug discovery for Alzheimer’s disease?
Juan F. González, J.M. Sánchez-Montero
Expert Opinion on Drug Discovery (2024) Vol. 19, Iss. 10, pp. 1149-1152
Open Access
Identification of high-affinity Monoamine oxidase B inhibitors for depression and Parkinson’s disease treatment: bioinformatic approach of drug repurposing
Moyad Shahwan, Pratibha Prasad, Dharmendra Kumar Yadav, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access
Page 1 - Next Page

Scroll to top